Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
US Department of Justice
US Army
Federal Trade Commission
Fish and Richardson

Generated: December 18, 2017

DrugPatentWatch Database Preview

LOTREL Drug Profile

« Back to Dashboard

Which patents cover Lotrel, and what generic alternatives are available?

Lotrel is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in LOTREL is amlodipine besylate; benazepril hydrochloride. There are fifty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the amlodipine besylate; benazepril hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
NovartisLOTRELamlodipine besylate; benazepril hydrochlorideCAPSULE;ORAL020364-002Mar 3, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
NovartisLOTRELamlodipine besylate; benazepril hydrochlorideCAPSULE;ORAL020364-007Apr 11, 2006ABRXYesNo► Subscribe► SubscribeYY► Subscribe
NovartisLOTRELamlodipine besylate; benazepril hydrochlorideCAPSULE;ORAL020364-003Mar 3, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
NovartisLOTRELamlodipine besylate; benazepril hydrochlorideCAPSULE;ORAL020364-004Mar 3, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
NovartisLOTRELamlodipine besylate; benazepril hydrochlorideCAPSULE;ORAL020364-006Apr 11, 2006ABRXYesYes► Subscribe► SubscribeYY► Subscribe
NovartisLOTRELamlodipine besylate; benazepril hydrochlorideCAPSULE;ORAL020364-005Jun 20, 2002ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LOTREL

Drugname Dosage Strength RLD Submissiondate
amlodipine besylate and benazepril hydrochlorideCapsules5 mg/40 mg and 10 mg/40 mgLotrel11/17/2006
amlodipine besylate and benazepril hydrochlorideCapsules2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mgLotrel6/9/2004

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission
Express Scripts
Cantor Fitzgerald
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: